QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 1, 2009, Pages 6-13

  Karthikeyan, C ^a   Moorthy, N S Hari Narayana ^a   Trivedi, Piyush ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Inhibitors; MOE; Pyridinyl guanidines; QSAR; uPA

Indexed keywords

2 PYRIDINYLGUANIDINE DERIVATIVE; GUANIDINE DERIVATIVE; HALOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ANALYTIC METHOD; ARTICLE; ATOM; CHEMICAL BOND; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; LINEAR REGRESSION ANALYSIS; LIPOPHILICITY; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALKENES; ANIMALS; GUANIDINES; HALOGENS; HUMANS; HYDROPHOBICITY; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 58949091558     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701810355     Document Type: Article

References (15)

1. Dano, K., Andreasen, PA, Grondahl-Hansen, J., Kristensen, P., Nielsen, LS and Skriver, L. (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, pp. 139-266.
2. Rabbani, SA and Xing, RHM (1998) Role of urokinase and its receptor in invasion and metastasis of hormone-dependent malignancies. Int J Oncol, 12, pp. 911-920.
3. Irigoyen, JP, Munoz-Canoves, P., Montero, L., Koziczak, M. and Nagamine, Y. (1999) The plasminogen activator system: Biology and regulation. Cell Mol Life Sci, 56, pp. 104-132.
4. Sidenius, N. and Blasi, F. (2003) The urokinase plasminogen activator system in cancer. Cancer Metast Rev, 22, pp. 205-222.
5. Ellis, V., Pyke, C., Eriksen, J., Solberg, H. and Dano, K. (1992) The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci, 667, pp. 13-31.
6. Chapman, HA (1997) Plasminogen activators, integrins, and the coordinant regulation of cell adhesion and migration. Curr Opin Cell Biol, 9, pp. 714-724.
7. Giovanni, A. and David, PF (2005) Protease inhibitors in the clinic. Med Chem, 1, pp. 71-104.
8. Abderrahim, A., Stephanie, K., Gilles, T., Louis-Georges, S., Pnina, B., David, G. and Shafaat, AR (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res, 54:9, pp. 2372-2377.
9. Christopher, GB, Roger, PD and Valerie, AH (2002) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett, 12, pp. 181-184.
10. Christopher, GB and Roger, PD (2002) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-Substituted-5-halo-2-pyridinyl) guanidines. Bioorg Med Chem Lett, 12, pp. 185-187.
11. Heechung, Y., Jack, H., Ki, HK and Greer, J. (1990) Selective inhibition of urokinase by substituted phenylguanidines: Quantitative structure-activity relationship analyses. J Med Chem, 33:11, pp. 2956-2961.
12. Bhoomendra, AB, Veerappa, VG and Andanappa, KG (2005) 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: A comparative selectivity analysis. Bioorg Med Chem, 13, pp. 2773-2782.
13. Bhongade, BA and Gadad, AK (2004) 3D-QSAR CoMFA/CoMSIA studies on urokinase plasminogen activator (uPA) inhibitors: A strategic design in novel anticancer agents. Bioorg Med Chem, 12, pp. 2797-2805.
14. Cho, DH, Lee, SK, Kim, BT and No, KT (2001) Quantitative structure-activity relationship (QSAR) study of new fluorovinyloxyacetamides. Bull Korean Chem Soc, 22, pp. 388-394.
15. Kier, LB and Hall, LH (1977) Structure-activity studies on hallucinogenic amphetamines using molecular connectivity. J Med Chem, 20:12, pp. 1631-1636.